Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Nucl Med ; 64(11): 1806-1814, 2023 11.
Artículo en Inglés | MEDLINE | ID: mdl-37474270

RESUMEN

Inflammatory bowel disease (IBD), which includes both Crohn disease and ulcerative colitis, is a relapsing inflammatory disease of the gastrointestinal tract. Long-term chronic inflammatory conditions elevate the patient's risk of colorectal cancer (CRC). Currently, diagnosis requires endoscopy with biopsy. This procedure is invasive and requires a bowel-preparatory regimen, adding to patient burden. Interleukin 12 (IL12) and interleukin 23 (IL23) play key roles in inflammation, especially in the pathogenesis of IBD, and are established therapeutic targets. We propose that imaging of IL12/23 and its p40 subunit in IBD via immuno-PET potentially provides a new noninvasive diagnostic approach. Methods: Our aim was to investigate the potential of immuno-PET to image inflammation in a chemically induced mouse model of colitis using dextran sodium sulfate by targeting IL12/23p40 with a 89Zr-radiolabeled anti-IL12/23p40 antibody. Results: High uptake of the IL12/23p40 immuno-PET agent was exhibited by dextran sodium sulfate-administered mice, and this uptake correlated with increased IL12/23p40 present in the sera. Competitive binding studies confirmed the specificity of the radiotracer for IL12/23p40 in the gastrointestinal tract. Conclusion: These promising results demonstrate the utility of this radiotracer as an imaging biomarker of IBD. Moreover, IL12/23p40 immuno-PET can potentially guide treatment decisions for IBD management.


Asunto(s)
Colitis , Enfermedades Inflamatorias del Intestino , Humanos , Animales , Ratones , Interleucina-12/efectos adversos , Dextranos , Enfermedades Inflamatorias del Intestino/diagnóstico por imagen , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Inflamación , Tomografía de Emisión de Positrones , Sulfato de Dextran/efectos adversos , Modelos Animales de Enfermedad
2.
Theranostics ; 13(7): 2057-2071, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37153742

RESUMEN

Purpose: TRA-1-60 (TRA) is an established transcription factor of embryonic signaling and a well-known marker of pluripotency. It has been implicated in tumorigenesis and metastases, is not expressed in differentiated cells, which makes it an appealing biomarker for immunopositron emission tomography (immunoPET) imaging and radiopharmaceutical therapy (RPT). Herein, we explored the clinical implications of TRA in prostate cancer (PCa), examined the potential of TRA-targeted PET to specifically image TRA+ cancer stem cells (CSCs) and assessed response to the selective ablation of PCa CSCs using TRA-targeted RPT. Experimental Design: First, we assessed the relationship between TRA (PODXL) copy number alterations (CNA) and survival using publicly available patient databases. The anti-TRA antibody, Bstrongomab, was radiolabeled with Zr-89 or Lu-177 for immunoPET imaging and RPT in PCa xenografts. Radiosensitive tissues were collected to assess radiotoxicity while excised tumors were examined for pathologic treatment response. Results: Patients with tumors having high PODXL CNA exhibited poorer progression-free survival than those with low PODXL, suggesting that it plays an important role in tumor aggressiveness. TRA-targeted immunoPET imaging specifically imaged CSCs in DU-145 xenografts. Tumors treated with TRA RPT exhibited delayed growth and decreased proliferative activity, marked by Ki-67 immunohistochemistry. Aside from minor weight loss in select animals, no significant signs of radiotoxicity were observed in the kidneys or livers. Conclusions: We successfully demonstrated the clinical significance of TRA expression in human PCa, engineered and tested radiotheranostic agents to image and treat TRA+ prostate CSCs. Ablation of TRA+ CSCs blunted PCa growth. Future studies combining CSC ablation with standard treatment will be explored to achieve durable responses.


Asunto(s)
Células Madre Pluripotentes , Neoplasias de la Próstata , Masculino , Animales , Humanos , Radioisótopos , Circonio , Tomografía Computarizada por Rayos X , Neoplasias de la Próstata/diagnóstico por imagen , Neoplasias de la Próstata/metabolismo , Radiofármacos , Células Madre Pluripotentes/metabolismo , Línea Celular Tumoral
3.
Cancer Res ; 78(19): 5706-5717, 2018 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-30115693

RESUMEN

IFNγ is an attractive target for imaging active antitumor immunity due to its function in the T-cell signaling axis. Here, we test an IFNγ immuno-PET (immunoPET) probe for its capacity to identify adaptive immunotherapy response after HER2/neu vaccination in both spontaneous salivary and orthotopic neu+ mouse mammary tumors. IFNγ immunoPET detected elevated cytokine levels in situ after vaccination, which inversely correlated with tumor growth rate, an indicator of response to therapy. In a model of induced T-cell anergy where CD8 T cells infiltrate the tumor, but upregulate PD-1, IFNγ tracer uptake was equivalent to isotype control, illustrating a lack of antitumor T-cell activity. The IFNγ immunoPET tracer detected IFNγ protein sequestered on the surface of tumor cells, likely in complex with the IFNγ receptor, which may explain imaging localization of this soluble factor in vivo Collectively, we find that the activation status of cytotoxic T cells is annotated by IFNγ immunoPET, with reduced off-target binding to secondary lymphoid tissues compared with imaging total CD3+ tumor-infiltrating lymphocytes. Targeting of soluble cytokines such as IFNγ by PET imaging may provide valuable noninvasive insight into the function of immune cells in situ Significance: This study presents a novel approach to monitor therapeutic outcomes via IFNγ-targeted positron emission tomography. Cancer Res; 78(19); 5706-17. ©2018 AACR.


Asunto(s)
Inmunoterapia , Interferón gamma/metabolismo , Neoplasias/diagnóstico por imagen , Neoplasias/terapia , Tomografía de Emisión de Positrones , Animales , Unión Competitiva , Complejo CD3/metabolismo , Linfocitos T CD8-positivos/citología , Línea Celular Tumoral , Islas de CpG , Femenino , Heterocigoto , Activación de Linfocitos , Linfocitos Infiltrantes de Tumor/inmunología , Neoplasias Mamarias Animales/diagnóstico por imagen , Neoplasias Mamarias Animales/patología , Neoplasias Mamarias Animales/terapia , Ratones , Ratones Endogámicos BALB C , Trasplante de Neoplasias , Receptor de Muerte Celular Programada 1/metabolismo , Radiofármacos , Saliva/metabolismo , Linfocitos T Citotóxicos/citología
4.
Sci Rep ; 8(1): 9043, 2018 06 13.
Artículo en Inglés | MEDLINE | ID: mdl-29899472

RESUMEN

Tumor resistance to treatment paved the way toward the development of single agent drugs that target multiple molecular signatures amplified within the malignancy. The discovered crosstalk between EGFR and HER3 as well as the role of HER3 in mediating EGFR resistance made these two receptor tyrosine kinases attractive targets. MEHD7945A or duligotuzumab is a single immunotherapy agent that dually targets both molecular signatures. In this study, a positron emission tomography (PET) companion diagnostic to MEHD7945A is reported and evaluated in pancreatic cancer. Tumor accretion and whole body pharmacokinetics of 89Zr-MEHD7945A were established. Specificity of the probe for EGFR and/or HER3 was further examined.


Asunto(s)
Inmunoglobulina G/farmacología , Neoplasias Pancreáticas/terapia , Tomografía de Emisión de Positrones/métodos , Receptor ErbB-3/antagonistas & inhibidores , Animales , Anticuerpos Monoclonales/química , Anticuerpos Monoclonales/farmacocinética , Anticuerpos Monoclonales/farmacología , Antineoplásicos/química , Antineoplásicos/farmacocinética , Antineoplásicos/farmacología , Línea Celular Tumoral , Receptores ErbB/antagonistas & inhibidores , Receptores ErbB/metabolismo , Femenino , Humanos , Inmunoglobulina G/química , Ratones SCID , Neoplasias Pancreáticas/diagnóstico por imagen , Neoplasias Pancreáticas/metabolismo , Radioisótopos/química , Receptor ErbB-3/metabolismo , Ensayos Antitumor por Modelo de Xenoinjerto , Circonio/química
5.
Am J Nephrol ; 38(6): 465-74, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24296691

RESUMEN

INTRODUCTION: Excretion of monoclonal free light chains (MFLC) beyond the renal threshold can cause kidney injury, but evidence for polyclonal free light chains (PFLC)-mediated injury is limited. We aimed to study the degree of PFLC deposition in the proximal tubules of chronic kidney disease (CKD) and hypothesized that excess deposition may contribute to tubular injury. METHODS: In this retrospective study, immunohistochemical staining to assess the degree of FLC deposition, periodic acid-Schiff staining for the degree of tubular brush border injury and trichrome staining for interstitial fibrosis were evaluated. Normal renal parenchyma from tumor nephrectomy specimens (control group I, n = 39), minimal change disease controls (group II, n = 13), renal biopsies from CKD and proteinuria (polyclonal study group III, n = 33) and monoclonal light chain nephropathy (group IV, n = 37) were studied. The results of the study including serum creatinine were compared between groups. RESULTS: Both polyclonal and monoclonal groups (groups III and IV) had significantly higher light chain deposition and brush border injury by periodic acid-Schiff scores compared to control groups (groups I and II). When the first three polyclonal groups (groups I-III) were analyzed together, polyclonal light chain deposition was significantly correlated with serum creatinine levels, brush border injury and interstitial fibrosis. CONCLUSION: The results of our study suggest that in CKD patients with proteinuria, excess PFLC deposition in the proximal tubules may cause acute tubular injury akin to monoclonal gammopathy and lead to renal chronicity.


Asunto(s)
Cadenas Ligeras de Inmunoglobulina , Enfermedades Renales/patología , Túbulos Renales/patología , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales/química , Creatinina/sangre , Femenino , Fibrosis , Humanos , Inmunohistoquímica , Riñón/lesiones , Túbulos Renales Proximales/patología , Masculino , Persona de Mediana Edad , Proteinuria/fisiopatología , Insuficiencia Renal Crónica/inmunología , Insuficiencia Renal Crónica/patología , Estudios Retrospectivos
6.
Ann Clin Lab Sci ; 40(4): 324-9, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20947805

RESUMEN

BK virus infection is a significant threat to renal transplant outcome. Detecting viral infection in renal transplant biopsies using SV40 staining is less than ideal. SV40 antibody reacts with the large T-antigen of BK virus only at the early phases of infection and can miss cells in later stages of infection. As p53 is upregulated during both early and late phases of infection, this study set out to determine whether p53 staining could improve detection of BK virus infection in renal transplant patients. The control group consisted of 16 renal allograft biopsies without histologic evidence of BK virus infection, while the BK group consisted of 15 renal allograft biopsies with histologic evidence of BK virus infection. The biopsies from both groups were immunohistochemically stained with both SV40 and p53 antibodies. Dual staining with both markers was also performed to identify their nuclear co-localization. In the BK group, the percent of p53 staining (16.6 ± 4.8 %) was significantly higher than the percent of SV40 staining (5.4 ± 2.7%). BK virus infected cells revealed a unique p53 immunostaining pattern (strong nuclear staining with a central halo). Co-localization of SV40 and p53 was identified in cells that had characteristic nuclear features of BK virus infection by histology. The sensitivity and specificity for using p53 staining to identify BK infected cells was 92% and 86 %, respectively. In conclusion, p53 staining detects a higher percentage of BK virus infected cells than SV40 staining alone. Thus, for diagnosis of BK virus infection in renal allograft biopsies, p53 staining is a sensitive and specific method when used along with SV40 staining.


Asunto(s)
Virus BK/aislamiento & purificación , Virus BK/fisiología , Trasplante de Riñón , Infecciones por Polyomavirus/diagnóstico , Proteína p53 Supresora de Tumor/metabolismo , Biomarcadores/metabolismo , Biopsia , Humanos , Inmunohistoquímica , Infecciones por Polyomavirus/metabolismo , Infecciones por Polyomavirus/virología , Virus 40 de los Simios/metabolismo , Trasplante Homólogo , Proteína p53 Supresora de Tumor/análisis , Proteína p53 Supresora de Tumor/inmunología
7.
Biotechnol Prog ; 19(2): 273-80, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12675559

RESUMEN

Metallothioneins (MTs) are metal-binding proteins that confer heavy metal tolerance and accumulation in yeast. To augment higher plant metal sequestration, the yeast metallothionein (CUP 1) was introduced into tobacco plants. The CUP 1 gene expression and copper and cadmium phytoextraction were determined. To confirm transformation, selfed and kanamycin-resistant third generation plants were subjected to DNA blot and polymerase chain reaction (PCR) analysis. A 4 mM CuSO(4) stress for 7 days resulted in a decline in CUP 1 transcripts versus nonstress conditions. Despite low mRNA levels, CUP 1 transformants accumulated up to seven times more copper in older versus younger leaves during copper stress. Pooled leaves of transgenic plants grown in soils from copper stamp-sands contained two to three times the copper content as that of the control plants. Unlike some previous reports featuring MT overexpression in plants, CUP 1 seedlings did not significantly sequester or demonstrate tolerance to CdCl(2). Using this transgenic approach, yeast CUP 1 expression under nonstressed conditions contributed to copper metal phytoextraction during a subsequent copper challenge. This strategy could be incorporated into plants designed for enhanced phytoremediation of metal contaminants.


Asunto(s)
Cobre/metabolismo , Metalotioneína/genética , Metalotioneína/metabolismo , Nicotiana/genética , Nicotiana/metabolismo , Plantas Modificadas Genéticamente/metabolismo , Ingeniería de Proteínas/métodos , Contaminantes del Suelo/metabolismo , Secuencia de Aminoácidos , Biodegradación Ambiental , Proteínas Fúngicas/genética , Proteínas Fúngicas/metabolismo , Regulación de la Expresión Génica de las Plantas , Residuos Industriales/prevención & control , Datos de Secuencia Molecular , Hojas de la Planta/genética , Hojas de la Planta/metabolismo , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Eliminación de Residuos/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...